Asuka Okada

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

Yoshihiko Sakata, Shinya Sakata, Yuko Oya et al. · European Journal of Cancer · 2021 · 89 citations

Medicine, Oncology, Pharmacology +12

Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)

Go Saito, Yuko Oya, Yoshihiko Taniguchi et al. · Lung Cancer · 2021 · 58 citations

Medicine, Oncology, Radiation Oncology +15

Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer

Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya et al. · JAMA Network Open · 2023 · 29 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan

Makoto Hibino, Kiyoaki Uryu, Takayuki Takeda et al. · Journal of Thoracic Oncology · 2022 · 22 citations · Full text

Veterinary Medicine, Immunology, Oncology +17

Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study

Hayato Kawachi, Motohiro Tamiya, Yoshihiko Taniguchi et al. · JTO Clinical and Research Reports · 2022 · 15 citations · Full text

Medicine, Oncology, Pharmacotherapy +17